Background
Csaba Truckai invented a device for treating abnormal uterine bleeding (endometrial ablation) and assigned his patent rights to Hologic’s predecessor company. Truckai later founded Minerva Surgical and developed a competing endometrial ablation device. Hologic sued Minerva for infringement, and Minerva sought to defend the suit by arguing that Hologic’s patent claims were invalid. Hologic invoked the doctrine of assignor estoppel — a doctrine holding that an inventor who assigns a patent to an employer or purchaser is thereafter estopped from challenging the validity of the assigned patent in a subsequent infringement suit.
The district court and Federal Circuit upheld assignor estoppel as a complete bar to Minerva’s invalidity challenge. The Supreme Court granted certiorari to decide whether assignor estoppel should be abolished or whether the Federal Circuit had applied it too broadly.
The Court’s Holding
The Supreme Court upheld assignor estoppel but limited its scope. Writing for a 5-4 majority, Justice Kagan held that the doctrine remains valid and serves important purposes: when an inventor assigns a patent and represents — implicitly or explicitly — that the patent covers valid claims, fairness principles (estoppel) prevent the inventor from later making the contrary representation that the claims are invalid. A party cannot “[a]ssign [a] patent and [at the same time] set it at naught.”
However, the majority held that assignor estoppel is limited to cases where there is a direct conflict between the invalidity position the assignor now asserts and what the assignor warranted in making the assignment. Critically, the doctrine does not extend to claims that did not exist at the time of assignment and that the assignor therefore never warranted. If the patent holder later broadened the claims (through continuation applications or otherwise) to reach subject matter the inventor never assigned, the inventor is not estopped from challenging those broadened claims — because the inventor never represented that those claims were valid.
Key Takeaways
- Assignor estoppel remains a valid doctrine — an inventor who assigns a patent cannot later assert invalidity in a suit brought by the assignee or those claiming under the assignment.
- The doctrine is limited to direct conflicts: the estoppel applies only to claims that the inventor assigned and thereby warranted — not to claims that were later broadened or added to the patent after assignment.
- Inventors and their subsequent employers who compete with former employers should carefully compare the claims being asserted against them with the claims that existed at the time of assignment — if the asserted claims are broader or different from what was assigned, assignor estoppel may not apply.
- Patent holders seeking to enforce assigned patents against inventor-founded competitors should be aware that claim broadening after assignment may create gaps in assignor estoppel’s protection.
Why It Matters
Minerva Surgical v. Hologic addressed a doctrine that directly affects inventors’ career mobility and the competitive dynamics of technology industries where inventors commonly move between companies, start new ventures, and compete with their former employers. The Supreme Court’s preservation of assignor estoppel — while limiting its scope to claims actually assigned — balanced the fairness concerns on both sides: inventors cannot simultaneously take value from an assignment and then undermine its basis, but they are also not permanently barred from challenging all future broadening of patents in the same family.
For the medical device industry — in which inventors commonly move between companies and compete in niche markets like endometrial ablation — the ruling has direct commercial significance. More broadly, Minerva clarified a doctrine that affects the settlement dynamics of any patent case where an inventor-defendant attempts to contest validity, and it provides guidance for how patent holders should draft assignment agreements and continuation patent applications to maximize assignor estoppel protection.